Category: News & Comments

Navidea Biopharmaceuticals: Why This Small Firm’s Stock Skyrocketed

Navidea Biopharmaceuticals Stock Soared Navidea Biopharmaceuticals (NAVB) stock price jumped from $1.27 to $3.04 this morning. The reason for the stock’s soaring, according to the firm’s press release, was that interim data from a trial have further corroborated Navidea’s hypotheses that Tc99m tilmanocept imaging can provide robust, quantitative imaging in healthy controls as well as in patients with active rheumatoid arthritis (RA). Furthermore, this imaging …
Moderna: Positive Interim Phase 1 Data for its mRNA-1273 Vaccine Against Novel Coronavirus

Moderna: Positive Interim Phase 1 Data for its mRNA-1273 Vaccine Against Novel Coronavirus

Moderna Postive News for mRNA-1273 Vaccine Against Novel Coronavirus (COVID-19) Moderna (MRNA) announced positive interim clinical data of mRNA-1273, its vaccine candidate against novel coronavirus (SARS-CoV-2 or COVID-19), from the Phase 1 study led by the National Institute of Allergy and Infectious Diseases (NIAID) which is part of the National Institutes of Health (NIH). According to the firm’s press release, Immunogenicity data are currently available …

Sorrento Therapeutics: STI-1499 ~ An Encouraging Anti-SARS-CoV-2 Antibody

Sorrento Therapeutics Anti-SARS-CoV-2 Antibody STI-1499 Sorrento Therapeutics (SRNE) announced that its anti-SARS-CoV-2 antibody, STI-1499, demonstrated 100% inhibition of SARS-CoV-2 (COVID-19) virus infection in an in vitro virus infection experiment at a very low antibody concentration. Sorrento has screened billions of antibodies in its proprietary G-MAB™ fully human antibody library and has so far identified hundreds of antibody candidates that bind the S1 subunit of the SARS-CoV-2 Spike protein. …

Alexion Pharmaceuticals to Acquire Portola at $18 Per Share

Alexion to Acquire Portola Alexion (ALXN) and Portola (PTLA) entered into a definitive merger agreement and Alexion acquired Portola. The Terms of the Merger A subsidiary of Alexion will commence a tender offer to acquire all of the outstanding shares of Portola’s common stock at a price of $18 per share in cash. The tender offer is subject to customary conditions including the tender of …

Moderna: Speeding down the Road Towards Developing a Prophylactic Vaccine Against the Novel Coronavirus (SARS-CoV-2)

Moderna Submitted an IND for Its mRNA Vaccine Candidate for Novel Coronavirus  Moderna (MRNA) announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its mRNA vaccine candidate, mRNA-1273, against the novel coronavirus, SARS-CoV-2. The filing is for the evaluation in Phase 2 and for late-stage studies if supported by safety data from the Phase …

Compugen: A New Important Patent from Europe and Much More

Compugen: In the NEWS Compugen (CGEN) was granted a new patent for the composition of COM701 or backup antibodies for the treatment of cancer by the European Patent Office (EPO). The EPO Patent No. 3295951 titled, “Anti-PVRIG Antibodies and Methods of Use”, covers the composition of matter for COM701 and backup antibodies including any anti-PVRIG antibody having the binding fragments of COM701 or backup antibodies …
Why Gilead’s and Moderna’s Stocks Rallied Today

Why Gilead’s and Moderna’s Stocks Rallied Today

Gilead Sciences Gilead (GILD) stock soared after market hours adding $11 to the $1.90 the stock had gained during trading hours. Investors’ enthusiasm was raised when very promising results came out of a clinical trial for Gilead’s drug remdesivir given to COVID-19 infected people.   According to the news the University of Chicago’s Phase 3 trial results demonstrated that most COVID-19 infected patients treated with …
Compugen: A Small Firm with Giant Technological Capabilities

Compugen: A Small Firm with Giant Technological Capabilities

Compugen to Present Data Update on COM701 Phase 1 Clinical Trial at the 2020 AACR Virtual Annual Meeting Compugen (CGEN) announced that it will present updates on its ongoing Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targeting PVRIG for the treatment of advanced solid tumors, in an oral presentation at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting I …
Its All About Coronavirus

Its All About Coronavirus

Coronavirus: The Possible Treatments While Moderna’s (MRNA) vaccine is being tested and its stock price continued to rise in the worst market performance day; other companies demonstrated readiness to bring their vaccines against the life-threatening virus into human clinical trials in the next few months. Regeneron (REGN) is one of the most trusted companies. In collaboration with Sanofi (SNY) the companies are on the top of …
Gilead Sciences To Acquire Forty Seven at $95.50 a Share in Cash

Gilead Sciences To Acquire Forty Seven at $95.50 a Share in Cash

Gilead Sciences to Acquire Forty Seven Gilead Sciences (GILD) and Forty Seven (FTSV) announced today that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Forty Seven for $95.50 per share in cash. The transaction, which values Forty-Seven at approximately $4.9 billion, was unanimously approved by both the Gilead and Forty Seven Boards of Directors and is anticipated to close during the second quarter …
More About Moderna, Gilead and Forty Seven

More About Moderna, Gilead and Forty Seven

Moderna Therapeutics Among all the firms announcing their interest in working towards designing and producing a preventive vaccine for COVID-19 only Moderna (MRNA) has accomplished that job and delivered it to the health authorities to decide upon the next step. Moderna’s stock soared. The stock did not go up in expectation of the millions . . . This content is for paid subscribers. Please click here …
Biotech Stocks Expected to Outperform in Today’s Tumbling Market

Biotech Stocks Expected to Outperform in Today’s Tumbling Market

Gilead and Moderna Stocks Will Outperform Today As stated in Prohost Letter #439 Gilead (GILD) investigational product remdesivir has offered hope towards treating infected people with COVID-19. Regarding the possibility of rapidly designing, creating and developing a preventive vaccine against COVID-19 Moderna Therapeutics (MRNA) seems to have accomplished this task. That’s why we were confident that Gilead’s and Moderna’s stocks will outperform today in a …
CRISPR Therapeutics and Sisters

CRISPR Therapeutics and Sisters

CRISPR, Intellia and Editas CRISPR Therapeutics (CRSP) announced revenues of Q4 2019 that beat analysts’ expectations. Based on the good news the stock market’s technicians contributed to boosting the stock’s price enabling the stock to recuperate a large part of its unwarranted recent selloff losses. New investors, who finally heard about the CRISPR gene editing technique and the Companies that specialize in it, seem to …
Why Moderna Stock Is Boosted in Today’s Bad Stock Market Day

Why Moderna Stock Is Boosted in Today’s Bad Stock Market Day

Coronavirus On January 7, 2020, a novel coronavirus (2019-nCoV) was identified in humans in Wuhan City, Hubei Province, China. Additional cases have been found in the United States and in a growing number of countries around the world.    Coronaviruses are a family of viruses that can lead to respiratory illness, including Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV). Coronaviruses are …
The Beginning of a Nektar Outperformance?

The Beginning of a Nektar Outperformance?

Nektar Therapeutics and Bristol-Myers Squibb Agreement Nektar Therapeutics (NKTR) and Bristol-Myers Squibb (BMY) announced their agreement for a new joint development plan aimed at advancing the combination of Nektar’s bempegaldesleukin (bempeg) + Bristol-Myers’ Opdivo (nivolumab) into multiple new registrational trials. The decision is based on a revision of the strategic collaboration agreement. It includes a new plan where both firms will expand the active clinical development …
Can Cassava Sciences Product PTI-125 Beat Alzheimer’s Disease?

Can Cassava Sciences Product PTI-125 Beat Alzheimer’s Disease?

Cassava Sciences Stock is Rallying Cassava Sciences (SAVA) stock closed on Friday, December 27, 2019 at $5.21, reaching a 52-week high. Today, December 30, 2019 the stock is jumping higher, trading now at $6.40, UP $1.19 despite the underperforming market today. The reason for investors’ rush to buy the stock is due to the good news from a Phase 2 trial of Cassava’s Alzheimer Disease …
Amylyx Pharmaceuticals: Clinical Trial Results Demonstrate Statistically Significant Treatment Benefit in Lou Gehrig’s Disease Patients

Amylyx Pharmaceuticals: Clinical Trial Results Demonstrate Statistically Significant Treatment Benefit in Lou Gehrig’s Disease Patients

Amylyx Pharmaceuticals With the advancement of biological sciences, and increased information about the pathways of diseases, we are getting more interested in biotech firms that are focused on treating life-threatening diseases as the risk of failure is decreasing.  The successful outcome of trials would tremendously boost the values of these firms as we have witnessed in many small biotech firms that became large firms and …
Exelixis and Genentech (Roche) Combination Beats Untreated BRAF V600-Mutation Positive Advanced Melanoma

Exelixis and Genentech (Roche) Combination Beats Untreated BRAF V600-Mutation Positive Advanced Melanoma

Exelixis Positive Results from IMspire 150 Exelixis (EXEL) announced positive results from IMspire 150; the phase 3 trial of atezolizumab (TECENTRIQ®), cobimetinib (COTELLIC®) and vemurafenib (ZELBORAF®) in people with previously untreated BRAF V600 mutation-positive advanced melanoma.  The IMspire150 study met its primary endpoint of progression-free survival (PFS). Adding atezolizumab to cobimetinib and vemurafenib helped reduce the risk of disease worsening or death, compared to placebo plus …
Gilead’s CAR T Product Yescarta Demonstrates Positive Survival Results

Gilead’s CAR T Product Yescarta Demonstrates Positive Survival Results

Gilead’s CAR-T Product Yescarta Results Kite, a Gilead (GILD) subsidiary, announced new data from the ZUMA-1 trial of the CAR T Yescarta (axicabtagene ciloleucel) in adult patients with refractory large B-cell lymphoma. The data from the pivotal phase 2 study demonstrate that patients with refractory large B cell lymphoma were alive three years following a single infusion of Gilead’s CAR T immuno-oncology product Yescarta.  Analysis from …
Novartis to Acquire The Medicines Company at $85 a Share

Novartis to Acquire The Medicines Company at $85 a Share

Novartis to Acquire The Medicines Company Novartis (NVS) decided to buy The Medicines Company (MDCO) at $6.8 million. The Medicines Company’s shareholders will be getting $85 per share in cash  – a 45% premium to its unaffected share price and a 57% premium to its unaffected one-week average price. The Transaction is expected to be completed in the first quarter of 2020 The Medicines Company …